Cannabigerol (CBG), a non-psychoactive cannabinoid found in cannabis, has emerged as a promising therapeutic agent with a diverse range of potential applications. Unlike its well-known counterpart tetrahydrocannabinol (THC), CBG does not induce intoxication, making it an attractive option in the clinic. Recent research has shed light on CBG’s intriguing molecular mechanisms, highlighting its potential to modulate multiple physiological processes. This review delves into the current understanding of CBG’s molecular interactions and explores its therapeutic power to alleviate various conditions, including cancer, metabolic, pain, and inflammatory disorders, amongst others. We discuss how CBG interacts with the endocannabinoid system and other key signaling pathways, such as CB1, CB2, TPR channels, and α2-adrenoceptor, potentially influencing inflammation, pain, neurodegeneration, and other ailments. Additionally, we highlight the ongoing research efforts aimed at elucidating the full spectrum of CBG’s therapeutic potential and its safety profile in clinical settings. Through this comprehensive analysis, we aim to provide a deeper understanding of CBG’s role in promoting human health and pave the way for future research endeavors.
9 October 2024 in Prostaglandins & Other Lipid Mediators
Anxiety is a prevalent mental health disorder that significantly impairs daily functioning and social interactions. While pharmacological treatments can be effective, they are often limited by challenges such as treatment resistance, side effects, and relapse. Electroacupuncture (EA) has emerged as a promising non-pharmacological intervention for anxiety, though its mechanisms of action remain largely unexplored. This study investigates the role of microglial cells in anxiety and examines how EA influences microglial morphology and function in the basolateral amygdala (BLA) in a model of social isolation-induced anxiety. Using a socially isolated mouse model, we assessed anxiety-like behaviors through the Elevated Plus Maze (EPM) and Open Field Test (OFT), and conducted biochemical analyses and immunofluorescence imaging to evaluate NOX2 expression, microglial activation, and oxidative stress markers. Our results show that EA significantly alleviates anxiety-like behaviors, reduces NOX2 expression in BLA microglia, lowers reactive oxygen species (ROS) levels, and enhances microglial morphology. These findings suggest that EA exerts its anxiolytic effects by modulating oxidative stress and microglial activity in the BLA, offering new insights into the cellular mechanisms by which EA may aid in anxiety management.